My ePortfolio Register   

Results of the AML 12 trial

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 11.12.17
Views: 598

Dr Ana Garrido - Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

Dr Garrido speaks with ecancer at the ASH 2017 annual meeting about results from 500 patients enrolled in a risk-adapted phase II trial of intensive chemotherapy followed or not by autologous or allogeneic HCT.

She outlines the cytogenetic and MRD classifications for high, intermediate and low-risk trial arms, and their improved survival endpoints based on risk stratification and subsequent treatment.

Dr Garrido hopes that further NGS validation will confirm markers for risk and response.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence